Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Naloxone shortage

Executive Summary

FDA contracts Canadian company Sabex to supply morphine antagonist pending shortage resolution. Narcan manufacturer Endo had experienced manufacturing difficulties due to DuPont plant shutdown (1"The Pink Sheet" March 26, In Brief). According to the American Society of Health-System Pharmacists, Endo plans to release back orders by early June, while Abbott expects releases in April and May. Sabex' naloxone will not be available for intrathecal use
Advertisement

Related Content

FDA Drug Shortage Role Should Focus On Prevention, GPOs Suggest
FDA Drug Shortage Role Should Focus On Prevention, GPOs Suggest
Endo Narcan
Endo Narcan
Advertisement
UsernamePublicRestriction

Register

PS037667

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel